A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly-Reference-Cited by-同舟云学术

A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly

Published:2021-09-21 Issue:12 Volume:14 Page:1049-1058
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Leleu Xavier¹,Chari Ajai²^ORCID,Richard Shambavi²,Khurana Monica³,Yusuf Akeem³,Usmani Saad Z.⁴

Affiliation:

1. CHU and Inserm, Poitiers, 1402 CIC, France

2. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

3. Amgen Inc, Thousand Oaks, USA

4. Levine Cancer Institute/Atrium Health, Charlotte, NC, USA

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2021.1955343

Reference79 articles.

1. Cancer statistics, 2020

2. World Health Organization. International Agency for Research on Cancer: multiple myeloma fact sheet. 2018.

3. Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model

4. Relapsed refractory multiple myeloma: a comprehensive overview

5. SARCLISA (Isatuximab-irfc). Full prescribing information, Sanofi-Aventis US LLC, Bridgewater, NJ, 2021.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review of daratumumab efficacy in all monoclonal gammopathies and other diseases and our experience with daratumumab, lenalidomide and dexamethasone therapy in 74 patients;Onkologie;2022-10-14